Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 19/20 | 0.77 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
| ▸ | FPR3 | P25089 | 1/20 | 0.53 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586566 | 0.91 | CCR1 (0.79) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL4586570 | 0.91 | CCR1 (0.79) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL4586561 | 0.91 | CCR1 (0.79) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6255070 | 0.91 | CCR1 (0.75) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6248125 | 0.90 | CCR1 (0.80) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6400200 | 0.90 | CCR1 (0.80) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL4587760 | 0.90 | CCR1 (0.72) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6077257 | 0.89 | CCR1 (0.84) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL4589534 | 0.89 | CCR1 (0.73) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL4588384 | 0.88 | CCR1 (0.83) | CCR1PTGDR2FPR3GPR65GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713483-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | Schering Aktiengesellschaft (DE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077372-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-25 | — | — | WO | disclosed |